Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another 11% for HNAB already! Congrats... Do you have a price target on it? Thinking about jumping in, but might wait and see if it retraces a bit...
HNAB is really moving today... Great volume for only an hour after open!
GLTA.
HNAB (.297) up 9%! .30 last resistance until 0.47, increasing volume.
POZN - Brean Murray ups POZN to $14 from $11.
From Schwab News.
POZN ($10.97)... Analyst thoughts on POZN and its potential for Vimovo approval!
Dr. Jonathan Aschoff, Ph.D., is a Senior Equity Analyst at Brean Murray, Carret & Co., LLC
http://finance.yahoo.com/news/Arthritis-Drug-Vimovo-twst-3473823072.html?x=0&.v=1
POZN ($10.97)with FDA decision on Vimovo coming on (or before) april 30:
The decision whether or not to approve Pozen Inc.'s Vimovo, an investigational drug for the treatment of signs and symptoms of osteoarthritis , rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing *NSAID-associated gastric ulcers, will be issued by April 30. (*Non-steroidal Anti-inflammatory Drugs)
Vimovo is developed in partnership with AstraZeneca plc (AZN). The New Drug Application for Vimovo was submitted on June 30, 2009, and based on a standard 10-month review, the FDA decision date is April 30, 2010. Pozen's partner AstraZeneca is seeking approval of Vimovo in the European Union too.
Pozen, which has thus far received $80 million in upfront and milestone payments from AstraZeneca, is eligible to earn $20 million in milestone payment if Vimovo wins regulatory approval in the U.S. and another $25 million if the drugs gets approved outside of the U.S. Based on achievement of certain sales thresholds, Pozen is also entitled to receive sales performance milestones of $260 million.
Pozen shares, which have gained over 70% in the past three months, closed Friday's trading at $10.87 on a volume of 1.07 million shares.
Attention BioShockers Board: We now have a website...
www.bioshockers.com
Fully functional FDA & Clinical Trials calendar, blog, stock research section, etc...
Check it out...
Thanks for posting!
FDA CALENDAR FROM MAY 2010 TO OCTOBER 2010
DNDN MAY 1
QCOR MAY 6
APPY MAY 18
CXM JUNE 3
PGNX JUNE 4
DCTH JUNE 5
HNAB JUNE 7
OSUR JULY 7
VVUS JULY 15
BIEL JULY 19
KOOL JULY 30
JAV OCTOBER 3
ALXA OCTOBER 11
ISTA OCTOBER 16
ARNA OCTOBER 22
BIOD OCTOBER 30
Thank you very much Camaro! Will be exciting to set up a new board here... Will be doing some "promotion" of the board very soon to get more eyes and better discussion to the board!
Welcome thommygun88 as new assistant moderator for "BioShockers"!
Attention: portfolio tracker is now in the iBox
Do your own DD before investing!
GLTA.
BioShockers 2Q Watch List (updated)
RNN – release of Zoraxel P2a results
QCOR – advisory committee meeting scheduled for Acthar (drug for treatment of infantile spasms) on May 6
POZN – PDUFA date for VIOMOVO on 4/30
CYTX – APOLLO and PRECISE trial results to be presented at meeting on May 7
HRBR – release of Triolex P2 results in obese type 2 diabetes patients
BNVI – possible partner for Menerba
IVD – possible FDA decision on MAGO4S 510K submission
THTCF.PK (also on Toronto exchange: TH.TO) – advisory committee meeting on May 27
PTN - Potential partner for CHF drug.
HNAB.OB - potential runup in anticipation of ASCO presentation.
To all - please do your own DD before investing. This post is just a starting point for your own DD.
GLTA.
Please add yourself to the BioShockers email list.
To do this:
Click "Show iBox"
At the bottom of the iBox there will be a link that says "sign up for email alerts", click that, enter in your email, and you're good to go!
Everyone have a great weekend, and if you happen to have time, check the board! It should be 100% complete (w/ watch list and all) by Sunday night!
A lot of events are coming up in June for biotech companies... SNSS, HNAB, AEZS, CYCC, and the list goes on... Will be posting a fresh watchlist for the quarter this weekend along w/ seperate DD posts for each stock.
Thanks! I agree 100%... If you have any suggestions for the board, let me know!
2010 ASCO (American Society of Clinical Oncology) Annual Meeting is June 4-8, 2010 in Chicago, IL.
http://chicago2010.asco.org/
Sounds good camaro! Nice board, but way too quiet!!! Would be nice to set up a new solid biotech board here....
DNDN PDUFA date is coming up soon... If Provenge receives FDA Approval, a lot of these biotechs w/ cancer drugs could see a nice boost, IMHO.
GLTA.
Called DCTH back in $5s, now in 12s and they announce positive phase 3 data a few days back... Stay tuned to this board for more awesome picks like DCTH... From now on, whenever I alert a stcok, I'll be posting DD w/ the stock.
As always, do your own DD as well.
GLTA.
greggor,
Haven't seen you around in a while! How are things going?
Soon to have a portfolio tracker in the iBox... Will post current holdings...
GLTA.
Will be updating the 2Q watch list this weekend...
GLTA.
BioShockers board:
Please tell friends/other members on iHub about this board! 2010 is going to be a fantastic year!
GLTA.
BioShockers 2Q 2010 Watch List
RNN – release of Serdaxin and Zoraxel P2a results
GNVC – momentum play, possible bounce coming
QCOR – advisory committee meeting for Acthar on May 6
AVNR – release of full P3 results
ACUR – advisory committee meeting for Acurox on 4/23
POZN – PDUFA date on 4/30
CYTX – APOLLO trial results to be presented at meeting on May 7
BTIM – stem cell momentum play
INHX – release of interim FV100 data
HRBR – release of Triolex P2 results in obese type 2 diabetes patients
HLCS – bounce play
BNVI – possible partner for Menerba
IVD – possible FDA decision on MAGO4S 510K submission
ISCO.OB – stem cell momentum play
THTCF.PK (also on Toronto exchange: TH.TO) – advisory committee meeting on May 27
If any of these need corrections or if you have a stock you think should be added, let me know.
RNN doesn't look so great anymore... IMO, unless a miracle happens, Serdaxin is finished.
GNVC is a great bounce play, IMO. If their atonal therapy (TherATOH) works (and preclinical results look really promising), GNVC will fly...
GLTA.
UPDATE 2-Rexahn antidepressant fails in early mid-stage trial
Tue Apr 13, 2010 3:38pm EDT
Rexahn Pharmaceuticals, Inc.
* Overall study fails to achieve statistical significance
* Says patients on 5 mg Serdaxin improved in MADRS scores * Shares down 50 pct (Recasts; adds company comments, updates stock movement)
By Krishnakali Sengupta
BANGALORE, April 13 (Reuters) - Rexahn Pharmaceuticals Inc (RNN.A) said its experimental antidepressant drug Serdaxin did not achieve statistical significance in a mid-stage study, sending its shares down 50 percent in afternoon trade.
The study, however, showed the drug to be safe and well tolerated without the appearance of serious side effects that are commonly linked to certain currently marketed drugs for the treatment of major depressive disorder, Rexahn said in a statement.
"This study was a proof-of-concept study from our perspective. We were looking for a strong signal, which we did get in the severe patient population", President Rakesh Soni told Reuters.
Although the overall study -- on 77 patients -- did not achieve statistical significance, results from the subgroup analysis showed the drug to significantly improve Montgomery-Asberg Depression Rating (MADRS) scores in patients treated with 5 mg of Serdaxin for 8 weeks, compared to a dummy drug.
The MADRS rating is used to measure the severity of depressive episodes in patients with mood disorders.
The company said it plans to start a second mid-stage clinical trial in the second half this year and is currently in talks with several major pharmaceutical companies to co-develop the drug.
Soni said the second mid-stage study will enroll about 400 patients and will evaluate the drug's efficacy against similar drugs.
"We are in talks with several companies, evaluating partnerships, and we expect much higher milestone payments for the drug than what we had with Teva," Soni added.
In 2009, Rexahn entered into an agreement with Teva Pharmaceutical Industries (TEVA.TA) (TEVA.O) for the development of one its preclinical novel anti-cancer compounds, for which it is expected to receive a couple of hundred million dollars in a milestone payments.
Shares of the company fell to $1.82, but recovered some of the losses and were trading down 48 percent at $1.89 in afternoon trade Tuesday on the American Stock Exchange. (Reporting by Krishnakali Sengupta; Editing by Unnikrishnan Nair)
Looks good -- added it to the 2Q list in the iBox. Thanks!
BioShockers Alert
Picked up some QCOR @ $8.66...
Also picked up some AVNR @ $3.04...
GLTA.
Q2 BioStocks to watch list is in the iBOX... DD on those to come soon, then I'll send out an email to the email subscribers...
GLTA.
Going to work on the iBOX today... If any of you have any good ideas as what else we should put in there, post here or PM me...
We called RNN back in December @ 0.67
Friday, they closed @ $2.65 (according to Google Finance)
Great call on NWBO -- it's up 0.30 (27.52%) today.
DCTH up 0.42 (4.44%)
14 Biotech Stocks Facing FDA Approval:
http://www.thestreet.com/story/10719163/1/14-biotech-stocks-facing-fda-approval.html
We called DCTH (Delcath Systems, Inc.) @ $5.32 in February. Today, it's trading @ $9.33
Link back for original DCTH post...
Potential BioShocker - QCOR (Questcor Pharmaceuticals, Inc.)
Upcoming advisory panel meeting and PDUFA date.
Drug: Acthar for infantile spasms
PDUFA date: June 11
An FDA advisory panel will review the safety and efficacy of Acthar on May 6. The FDA's review of Acthar is expected to post to the agency's web site on May 4 or May 5.
Will be re-doing the iBOX this week... Time to get this board up and running!
Nope... I sold on the CRL news, it'll be a while before they resubmit their NDA, so from this point, it's more of a longer term hold, IMO.
Followers
|
22
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
567
|
Created
|
12/09/09
|
Type
|
Free
|
Moderator Camaro1093 | |||
Assistants |
Welcome to BioShockers
This board is to find those under-the-radar, high potential biotech companies.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Each quarter, I compile a list of biotech companies to watch. I'll post the list here on the board, as well as send out a message to board members -- don't forget to sign up for our email alerts.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
BioShockers Portfolio Tracker
Symbol | Buy PPS | Sell PPS | Date Bought | Date Sold |
HNAB.OB | $0.253 $0.343 $0.25 | 4/22/2010 4/27/2010 5/3/2010 | ||
AEZS | $1.29 | $1.18 | 4/14/2010 | 5/4/2010 |
SNSS | $1.03 $0.9018 | 4/27/2010 4/30/2010 | ||
ITMN | $10.68 | $11.38 | 5/4/2010 | 5/5/2010 |
CLDX | $7.65 | $7.85 | 5/6/2010 | 5/6/2010 |
JAZZ | $8.43 | 5/6/2010 | ||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |